SI3027209T1 - Protitelesa za anti-aktivin A in njihova uporaba - Google Patents

Protitelesa za anti-aktivin A in njihova uporaba

Info

Publication number
SI3027209T1
SI3027209T1 SI201431693T SI201431693T SI3027209T1 SI 3027209 T1 SI3027209 T1 SI 3027209T1 SI 201431693 T SI201431693 T SI 201431693T SI 201431693 T SI201431693 T SI 201431693T SI 3027209 T1 SI3027209 T1 SI 3027209T1
Authority
SI
Slovenia
Prior art keywords
activin
antibodies
Prior art date
Application number
SI201431693T
Other languages
English (en)
Inventor
Jesper Gromada
Esther Latres
Andrew J. Murphy
George D. Yancopoulos
Lori C. Morton
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of SI3027209T1 publication Critical patent/SI3027209T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI201431693T 2013-07-30 2014-07-30 Protitelesa za anti-aktivin A in njihova uporaba SI3027209T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361859926P 2013-07-30 2013-07-30
US201361864036P 2013-08-09 2013-08-09
US201361911834P 2013-12-04 2013-12-04
US201361913885P 2013-12-09 2013-12-09
PCT/US2014/048957 WO2015017576A1 (en) 2013-07-30 2014-07-30 Anti-activin a antibodies and uses thereof
EP14750421.1A EP3027209B1 (en) 2013-07-30 2014-07-30 Anti-activin a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SI3027209T1 true SI3027209T1 (sl) 2020-11-30

Family

ID=52427866

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431693T SI3027209T1 (sl) 2013-07-30 2014-07-30 Protitelesa za anti-aktivin A in njihova uporaba

Country Status (28)

Country Link
US (4) US9718881B2 (sl)
EP (4) EP4062937A1 (sl)
JP (5) JP6581085B2 (sl)
KR (2) KR102440044B1 (sl)
CN (2) CN105592858B (sl)
AU (2) AU2014296243B2 (sl)
BR (1) BR112016002164B1 (sl)
CA (1) CA2920071C (sl)
CL (1) CL2016000251A1 (sl)
CY (1) CY1123788T1 (sl)
DK (1) DK3027209T3 (sl)
EA (1) EA037926B1 (sl)
ES (1) ES2827673T3 (sl)
HK (1) HK1225322A1 (sl)
HR (1) HRP20201729T1 (sl)
HU (1) HUE052518T2 (sl)
IL (2) IL243822B (sl)
LT (1) LT3027209T (sl)
MX (2) MX371498B (sl)
PH (1) PH12016500182A1 (sl)
PT (1) PT3027209T (sl)
RS (1) RS61124B1 (sl)
SG (1) SG11201600731WA (sl)
SI (1) SI3027209T1 (sl)
TW (2) TWI655207B (sl)
UY (1) UY35682A (sl)
WO (1) WO2015017576A1 (sl)
ZA (1) ZA201601294B (sl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973559B1 (en) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2120999B1 (en) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3494986T3 (da) 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EA039118B1 (ru) * 2015-04-01 2021-12-07 Ридженерон Фармасьютикалз, Инк. Способ лечения прогрессирующей оссифицирующей фибродисплазии
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
AU2016255768B2 (en) 2015-04-29 2022-03-10 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
TWI824372B (zh) * 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
AU2017340504A1 (en) * 2016-10-05 2019-04-11 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
EP3525820A4 (en) * 2016-10-17 2020-09-16 Vanderbilt University ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
EP3538128A4 (en) * 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
DE102018103302A1 (de) * 2018-02-14 2019-08-14 Noonee Ag Tragbare Sitzhaltungshilfevorrichtung
CN111787981A (zh) * 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法
AU2019284762A1 (en) 2018-06-13 2020-11-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
AU2019401575A1 (en) * 2018-12-18 2021-06-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, GDF8 and Activin A
US20220242956A1 (en) * 2019-05-30 2022-08-04 Acceleron Pharma Inc. Actrii-binding proteins and uses thereof
CA3164168A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2022009769A (es) 2020-02-11 2022-11-09 Regeneron Pharma Anticuerpos anti-acvr1 y usos de los mismos.
WO2021257947A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
JP2023539107A (ja) * 2020-08-20 2023-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法
EP4387647A2 (en) * 2021-08-16 2024-06-26 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
WO2023154672A2 (en) * 2022-02-14 2023-08-17 Ohio University Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
TWI819587B (zh) * 2022-04-29 2023-10-21 洪慧妤 用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
TR200400621T2 (tr) 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
UA93855C2 (ru) 2003-12-31 2011-03-25 Шеринг-Плау Лтд. Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
AU2005219441A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. ALK7 and myostatin inhibitors and uses thereof
MXPA06010929A (es) 2004-03-23 2007-01-16 Lilly Co Eli Anticuerpos anti-miostatina.
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008509927A (ja) 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
ES2659114T3 (es) 2005-08-19 2018-03-13 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CN112457389A (zh) * 2005-11-23 2021-03-09 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
MY147468A (en) 2006-06-02 2012-12-14 Regeneron Pharma High affinity antibodies to human il-6 receptor
EA015916B1 (ru) 2006-09-05 2011-12-30 Эли Лилли Энд Компани Моноклональные антитела к миостатину и их применения
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
ATE550333T1 (de) 2007-11-05 2012-04-15 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
DK3494986T3 (da) 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
NZ604818A (en) * 2008-11-26 2014-07-25 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
RS56796B1 (sr) * 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
CN111787981A (zh) * 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法

Also Published As

Publication number Publication date
JP2016528232A (ja) 2016-09-15
KR20210129253A (ko) 2021-10-27
PH12016500182A1 (en) 2016-04-25
CN113845594A (zh) 2021-12-28
KR20160030581A (ko) 2016-03-18
IL270218B (en) 2021-01-31
KR102315694B1 (ko) 2021-10-21
HK1225322A1 (zh) 2017-09-08
KR102440044B1 (ko) 2022-09-06
CA2920071C (en) 2023-05-23
CY1123788T1 (el) 2022-03-24
IL243822B (en) 2019-11-28
ES2827673T3 (es) 2021-05-24
BR112016002164B1 (pt) 2023-12-19
WO2015017576A1 (en) 2015-02-05
AU2014296243A1 (en) 2016-03-03
AU2020200892A1 (en) 2020-03-05
CA2920071A1 (en) 2015-02-05
ZA201601294B (en) 2017-05-31
NZ716854A (en) 2022-03-25
MX2020001201A (es) 2021-01-28
MX371498B (es) 2020-01-31
HUE052518T2 (hu) 2021-05-28
US20180155416A1 (en) 2018-06-07
JP6923602B2 (ja) 2021-08-25
EP4062937A1 (en) 2022-09-28
NZ754959A (en) 2022-03-25
EA037926B1 (ru) 2021-06-08
US20150037339A1 (en) 2015-02-05
JP7440464B2 (ja) 2024-02-28
EP3027209B1 (en) 2020-09-02
HRP20201729T1 (hr) 2020-12-25
JP2022130593A (ja) 2022-09-06
MX2016001394A (es) 2016-08-03
LT3027209T (lt) 2020-12-28
DK3027209T3 (da) 2020-11-02
CN105592858B (zh) 2021-10-01
EA201690243A1 (ru) 2016-06-30
JP2021176887A (ja) 2021-11-11
UY35682A (es) 2015-02-27
TW201602133A (zh) 2016-01-16
BR112016002164A2 (pt) 2017-09-12
PT3027209T (pt) 2020-10-22
JP2022160619A (ja) 2022-10-19
US20210163583A1 (en) 2021-06-03
CL2016000251A1 (es) 2017-07-14
JP7496387B2 (ja) 2024-06-06
US10526403B2 (en) 2020-01-07
JP6581085B2 (ja) 2019-09-25
AU2020200892B2 (en) 2022-03-31
EP3730151A1 (en) 2020-10-28
CN105592858A (zh) 2016-05-18
JP2020011965A (ja) 2020-01-23
TW201920262A (zh) 2019-06-01
EP4059520A1 (en) 2022-09-21
US20230312699A1 (en) 2023-10-05
SG11201600731WA (en) 2016-02-26
IL243822A0 (en) 2016-04-21
RS61124B1 (sr) 2020-12-31
EP3027209A1 (en) 2016-06-08
US9718881B2 (en) 2017-08-01
TWI655207B (zh) 2019-04-01
AU2014296243B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
IL270218B (en) Anti-activin a antibodies and their uses
IL261743B (en) and their uses 33–il antibodies against
HK1232243A1 (zh) 抗- 抗體及其用途
IL261547B (en) Antibodies against pesidine and their uses
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
EP2953970A4 (en) TRANSTYRETIN ANTIBODIES AND USES THEREOF
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody